1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Age significantly influences presentation and patterns of care in patients with newly diagnosed diffuse large cell lymphoma (DLCL): Collective data from 5 centers participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project
    Meeting Abstract

    Rodriguez, M. A.; Czuczman, M. S.; Friedberg, J. W.; Kho, M. E.; LaCasce, A. S.; Millenson, M.; Auayporn, N.; Niland, J.; ter Veer, A.; Zelenetz, A. D.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: Efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy
    Meeting Abstract

    Richardson, P.; Chanan-Khan, A.; Schlossman, R.; Munshi, N.; Wen, P.; Briemberg, H.; Kuter, D.; Oaklander, A.; Lodial, S.; Hassoun, H.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Graft-versus-tumor activity against renal cell carcinoma in a mouse model of HSCT
    Meeting Abstract

    Ramirez-Montagut, T.; Chow, A.; Kochman, A. A.; Hubbard, V. M.; Suh, D.; Smith, O. M.; Sindhi, H.; Terwey, T. H.; Kim, T. D.; Waldman, E.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Response to immunizations following allogeneic HCT with adjuvant rituximab therapy
    Meeting Abstract

    Pao, M.; Papadopoulos, E. B.; Boulad, F.; Castro-Malaspina, H.; Jakubowski, A.; Kernan, N. A.; Perales, M.; Prockop, S.; Ford, R.; Young, J. W.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C.; Straus, D.; Portlock, C.; Hamlin, P.; Neylon, E.; Evans, A.; Winter, J.; Gordon, L.; more...
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease
    Meeting Abstract

    O'connor, O.; Straus, D.; Moskowitz, C.; Hamlin, P.; Portlock, C.; Gerecitano, J.; Neylon, E.; Colevas, D.; Zelenetz, A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Phase II study of boriezomib for castrate metastatic prostate cancer (PC)
    Meeting Abstract

    Morris, M. J.; Beekman, K. W.; Kelly, W. K.; Slovin, S. F.; Shaffer, D.; Eicher, C.; Chu, E.; Curley, T.; Delacruz, A.; Scher, H. I.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma
    Meeting Abstract

    Molina, A. M.; Advani, R.; Reddy, S.; Hoppe, R.; Friedberg, J. W.; Sadan, S.; Myskowski, P.; Kim, Y. H.; Horwitz, S. M.
    Blood (2005)

    Fulltext@MSK | Save
  • Generation of specific human CD8+T cell responses to the myeloproliferative disorder associated V617F mutated JAK2 kinase by use of analog peptide vaccine candidates
    Meeting Abstract

    May, R. J.; Korontsvit, T.; Zakhaleva, V.; Gomez, M.; Dao, T.; Scheinberg, D. A.
    Blood (2005)

    Fulltext@MSK | Save